Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 96.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 7,069 shares of the company’s stock after selling 221,848 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $59,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Rothschild Investment LLC acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter worth about $26,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $42,000. Atlanta Consulting Group Advisors LLC acquired a new stake in Amneal Pharmaceuticals during the 1st quarter valued at approximately $61,000. nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $62,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the first quarter worth $65,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of several recent research reports. Barclays upped their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Amneal Pharmaceuticals Stock Up 1.4 %

AMRX stock opened at $8.73 on Friday. Amneal Pharmaceuticals, Inc. has a 52-week low of $3.96 and a 52-week high of $8.95. The company’s 50-day simple moving average is $8.53 and its 200-day simple moving average is $7.54. The firm has a market cap of $2.70 billion, a P/E ratio of -14.08 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. The company had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.